Key Details

Symbol (NSE): CIPLA

Corporate Action: Amalgamation (Absorption)

Record Date: Not Specified

Nature of Scheme: Scheme of Amalgamation by Absorption

Entities Involved:

  • Transferor Company: Inzpera Healthsciences Limited (CIN: U74999MH2016PLC282701)
  • Transferee Company: Cipla Limited (CIN: L24239MH1935PLC002380)

Demerged Company: Inzpera Healthsciences Limited

Resulting Company: Cipla Limited

Share Entitlement Ratio: Since the Transferor Company is a wholly-owned subsidiary of the Transferee Company, all equity shares of the Transferor Company held by the Transferee Company shall be cancelled without any further act or deed. No issue and allotment of shares of the Transferee Company to shareholders of the Transferor Company.

Implied Capital Structure Impact: Not Specified (no change in capital structure of transferee company)

Post-Allotment Listing Plan: The resulting entity (Cipla Limited) will remain listed on BSE and NSE. No separate listing contemplated.

Regulatory and Approval Status:

  • NCLT approval granted on 18th August 2026 via order CA(CAA)/114/MB/2026
  • Board approvals obtained on 19th March 2026
  • Shareholder meetings dispensed with for Transferor Company (obtained consent affidavits from all 7 equity shareholders and 1 preference shareholder)
  • Creditor meetings dispensed with (no secured creditors in either company, obtained consent from sole unsecured creditor of Transferor Company)
  • SEBI/Stock Exchange observations: Filed for disclosure purposes only under Regulation 37(6) of SEBI Listing Regulations

Effective Date: Appointed Date fixed as 1st April 2026

Financial Rationale:

  • Enable appropriate consolidation of activities with pooling and more efficient utilization of resources
  • Achieve greater economies of scale and reduction in overheads and other expenses
  • Improve various operating parameters and competitive position of combined entity
  • Achieve greater efficiency in cash management and unfettered access to cash flows
  • Improved organizational capability and leadership through pooling of human capital
  • Cost savings from focused operational efforts, rationalization, standardization and simplification of business processes
  • Elimination of duplication and rationalization of administrative expenses
  • Reduction of multiplicity of entities, thereby reducing compliance costs

Impact on Shareholders:

  • No change in ownership structure for Cipla shareholders
  • No dilution effect as no new shares are being issued
  • Rights of creditors preserved as assets post-amalgamation will be sufficient to discharge claims
  • Net worth of Transferee Company shall remain positive post-implementation